Transcode Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 10
- Market Cap
- -
- Introduction
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics approved a 1-for-33 reverse stock split effective Dec. 4, 2024, aiming to meet Nasdaq's minimum bid price requirement. The split converts 33 shares into 1, reducing outstanding shares to ~696,233. No fractional shares will be issued; stockholders will have fractional shares rounded up. The CUSIP number will change to 89357L402.
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial
TransCode Therapeutics completes dosing in Phase 1a trial for TTX-MC138, targeting microRNA-10b in metastatic cancer, with no significant safety issues reported.
Related Clinical Trials:
TransCode Therapeutics Completes Initial Dosing of First
TransCode Therapeutics completes first cohort dosing in Phase 1a trial for TTX-MC138, targeting microRNA-10b in metastatic cancer, with no significant safety issues reported.
Related Clinical Trials:
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with TTX-MC138
TransCode Therapeutics announces dosing of first two patients in Phase 1 trial for TTX-MC138, an antisense oligonucleotide targeting microRNA-10b to treat metastatic cancer. Several additional patients are being screened for enrollment in the multicenter, open-label study evaluating safety and tolerability.
Related Clinical Trials:
© Copyright 2025. All Rights Reserved by MedPath